• Assure Holdings (IOM) has expanded its operations with its first neuromonitoring case in Nevada
  • The company has signed an agreement to serve eight hospitals in the state
  • It is now operating in twelve states across the U.S.
  • Assure Holdings provides intraoperative neuromonitoring services during invasive surgeries
  • Assure Holdings (IOM) is unchanged trading at $9.30 per share

Assure Holdings (IOM) has expanded its operations with its first neuromonitoring case in Nevada.

It has signed an agreement to serve eight hospitals in the state, primarily in the Las Vegas Metro Area.

It will begin working with five surgeons that specialize in neurosurgery and orthopedic spine surgery who perform approximately 2,000 procedures per year. 

The company is now operating in twelve states: Colorado, Texas, Louisiana, Utah, Pennsylvania, Michigan, South Carolina, Arizona, Kansas, Missouri, Nebraska and Nevada.

John A. Farlinger, Assure’s Executive Chairman and CEO, stated,

“We expect to grow rapidly in Nevada and are confident in our ability to take advantage of sizeable business development opportunities in the state. On a per capita basis, Las Vegas is among the largest spine surgery markets in the nation. Over the next year, we anticipate that Nevada will be among Assure’s fastest-growing markets.”

Assure Holdings provides intraoperative neuromonitoring services during invasive surgeries.

Assure Holdings (IOM) is unchanged trading at $9.30 per share as of 10:45 am ET.

More From The Market Online
labratory work

PharmaTher locks in FDA-assigned goal date of abbreviated NDA

PharmaTher Holdings (CSE:PHRM) locks in its U.S. FDA-assigned goal date of abbreviated new drug application for Oct. 29, 2024.

Optimi Health makes first international MDMA shipment

Optimi Health (CSE:OPTI) makes its first international shipment of MDMA to The Institute for Psychedelic Research at Tel Aviv University.

Oncolytics Biotech approved to expand pancreatic cancer program

Oncolytics Biotech (TSX:ONC), a cancer immunotherapy stock, receives ethics and German regulatory approvals for a new pancreatic cancer study.